Compare Nebius Group NV (NBIS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Travere Therapeutics Inc. Common Stock — how do they compare? Nebius Group NV trades at $180.04 (market cap $56.24B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Nebius Group NV is far larger — about 11.5× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 25 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NBIS | TVTX | |
|---|---|---|
Market Cap | $56.24B | $4.88B |
Volume | 17,483,721 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $286.69 | $67.52 |
52-Week Low | $73.87 | $26.79 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $58.36B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $206.86, down 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E 795.62, P/S 42.26) against modest profitability (net margin 3.13%, ROE 0.6%). Recent news highlights AI infrastructure growth potential but also insider selling and competitive risks.
Analyst consensus remains bullish with 82% buy ratings and a $288.67 price target, suggesting 40% upside. Key risks include high capital expenditure, negative cash flow from investing, and dependence on AI demand sustainability. The stock's outlook hinges on execution of its $37B backlog and GPU rental pricing trends.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
